Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

RO 7759065

Next Previous
Drug Profile

RO 7759065

Alternative Names: RG-6561; RO-7759065

Latest Information Update: 11 Feb 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Genentech
  • Class Antineoplastics
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Solid tumours

Most Recent Events

  • 29 Jan 2026 Discontinued - Phase-I for Solid tumours (Combination therapy, Late-stage disease, Metastatic disease, Recurrent) in USA, Australia, Canada, Spain (Parenteral) (Roche pipeline, January 2026)
  • 29 Jan 2026 Discontinued - Phase-I for Solid tumours (Late-stage disease, Metastatic disease, Monotherapy, Recurrent) in USA, Australia, Spain, Canada (Parenteral) (Roche pipeline, January 2026)
  • 24 Dec 2025 Genentech terminates a phase I trial in Solid tumours (Late-stage disease, Metastatic disease, Monotherapy, Combination therapy, Recurrent) in the US, Australia, Canada and Spain (Parenteral) following a thorough review of safety data, preliminary efficacy data and an evaluation of overall risk-benefit, Sponsor made the decision to end the study before December 2025 (NCT06488716)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top